SUMMIT, N.J., Oct. 21, 2025 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing ...

The Centers for Disease Control and Prevention released a report March 12 on the effectiveness of the flu vaccine for the ...

Vaccine effectiveness was 38 to 41 percent against influenza outpatient visits, 41 percent against flu-linked hospitalization ...

The FDA has approved a label update for Seqirus’s Flucelvax and Flucelvax Quadrivalent to include a warning about febrile seizures in young children. The new warning applies to children ages 6 months ...

To support global influenza vaccine research and development, Sino Biological has launched an extensive portfolio of recombinant antigens for the 2026-2027 Northern Hemisphere influenza vaccine ...

CSL Seqirus was granted a contract to support flu pandemic preparedness plans for Canada's government. The flu vaccine manufacturer said Friday it would make and deliver millions of doses of ...

The United States is facing one of its most severe flu seasons in decades, data show. Infections and hospitalizations are surging, driven by a new mutated influenza A variant, H3N2 "subclade K." ...